237 related articles for article (PubMed ID: 15788209)
1. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
4. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
[TBL] [Abstract][Full Text] [Related]
5. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
8. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
Hsu WC; Chan SC; Ting LL; Chung NN; Wang PM; Ying KS; Shin JS; Chao CJ; Lin GD
Jpn J Clin Oncol; 2006 Feb; 36(2):93-9. PubMed ID: 16517834
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis.
Wen J; Shen WL; Yang SH
Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):224-7. PubMed ID: 16698580
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
11. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
Lim TY; Cheong JY; Cho SW; Sim SJ; Kim JS; Choi SJ; Choi JW; Kwon HC; Lee KM; Kim JK; Won JH; Yoo BM; Lee KJ; Hahm KB; Kim JH
Korean J Hepatol; 2006 Mar; 12(1):65-73. PubMed ID: 16565607
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
13. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
Cipriani G; Mazzanti R
Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
[No Abstract] [Full Text] [Related]
14. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
17. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.
Villa E; Ferretti I; Grottola A; Buttafoco P; Buono MG; Giannini F; Manno M; Bertani H; Dugani A; Manenti F
Br J Cancer; 2001 Apr; 84(7):881-5. PubMed ID: 11286465
[TBL] [Abstract][Full Text] [Related]
18. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Ang SF; Tan SH; Toh HC; Poon DY; Ong SY; Foo KF; Choo SP
Am J Clin Oncol; 2012 Jun; 35(3):222-7. PubMed ID: 21378539
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
Ch'ang HJ; Hsu C; Chen CH; Chang YH; Chang JS; Chen LT
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):817-25. PubMed ID: 21277098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]